Fortress Biotech, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $63.3M | $57.7M | $84.5M | $75.7M | $68.8M |
| Operating income | -$70.2M | -$110.4M | -$142.3M | -$203.6M | -$188.5M |
| Cost of revenue | $20.9M | $20.9M | $22.9M | $30.8M | $32.1M |
| Cash from operations | -$65.8M | -$80.2M | -$128.2M | -$179.4M | -$116.5M |
| Capital expenditure | — | $0 | $63,000 | $2.7M | $4.6M |
| Free cash flow | — | -$80.2M | -$128.3M | -$182.1M | -$121.1M |
| Impairments | $0 | $3.7M | $3.1M | $0 | $0 |
| Total assets | $185.5M | $144.2M | $167.5M | $294.3M | $396.5M |
| Total liabilities | $123.4M | $145.9M | $165.9M | $244.3M | $170.6M |
| Total debt | — | — | — | — | $60.5M |
Shares outstanding 33.2M · Free float 45.3%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.